OMNIACTIVE WINS PRESTIGIOUS PHARMEXCIL’S GOLD PATENT AWARD WITH RECORD NUMBER OF GLOBAL PATENTS

OMNIACTIVE WINS PRESTIGIOUS PHARMEXCIL’S GOLD PATENT AWARD WITH RECORD NUMBER OF GLOBAL PATENTS

OmniActive Health Technologies, Ltd., won Pharmexcil’s Gold Patent Award in the category of nutraceuticals for fiscal year 2015-16. Adding value to the company’s strong patent portfolio, these patents cover OmniActive’s potential products, processes and platform technologies. An esteemed panel of experts honored OmniActive for their contribution as part of the Pharmexcil 8th Edition of Patents Award 2015-16. The award ceremony will take place in Hyderabad (India) at the Hotel Park Hyatt on Thursday, September 22 during the 12th Annual Meet following the CEO Conclave.

Pharmexcil—the Pharmaceuticals Export Promotion Council of India—was created by the government of India in May 2004 under the provision of Foreign Trade Policy by the Ministry of Commerce and Industry, which cover a variety of pharmaceutical products including bulk drugs, formulations, biotech products, Indian systems of medicines, herbal products, diagnostics and clinical research.

“We at OmniActive take pride in having built a portfolio of branded ingredients and proprietary platform technologies recognized by customers world-wide. The painstaking efforts and solution-oriented thinking of our scientists and technologists result in novel and innovative products, processes and applications. By addressing real market needs and expanding the scope for our established products, we create opportunities for our products of the future,” said Sanjaya Mariwala, Managing Director, OmniActive Health Technologies. “When a respected body like Pharmexcil recognizes the intellectual property we have developed through the prestigious Gold Patent Award, it validates our approach of science and innovation based growth for products which we supply to markets worldwide, reaffirming our continued commitment to make significant investments in science-based research, development and innovation.”

In addition to its award-winning ingredients and state-of-the-art manufacturing facilities, OmniActive is known for its global science and research teams who operate from R&D centers in Pune and Thane with much of the work tested out internationally through teams in the US as well as its Innovation Centre in Canada.

“As a result of our commitment to science and technology, OmniActive can truly make an international impact through the proposed advancements of our strong portfolio of patents and proprietary IP,” added Dr. Arun Balakrishnan, Chief Scientific Officer of OmniActive.

For more information on this award or to discuss our award-winning ingredients or technologies, please contact Lynda Doyle at l.doyle@omniactives.com.

About OmniActive Health Technologies

OmniActive Health Technologies (www.omniactives.com) offers a range of quality ingredients, that are innovative and scientifically validated to address complex challenges for customers in the dietary supplement, food and beverage space using technology-driven, sustainable solutions with application support within a global regulatory framework. OmniActive’s core products include carotenoids, plant extracts and specialty functional ingredients. The company develops IP-protected, science-backed branded ingredients from natural sources using cutting edge technologies. OmniActive leverages international R&D strengths to deploy an array of state of the art manufacturing technologies in extraction, purification, isolation and delivery of nutritional actives. Clinical research–geared towards demonstrating efficacy and claim substantiation–is the cornerstone of OmniActive’s R&D activities. The company’s centers of excellence are located in North America and India, whereas its cGMP and HACCP system-compliant manufacturing operations are located at multiple FDA-inspected sites in India. Whether looking for a new ingredient to add to a finished product, or technology to enhance an existing ingredient, OmniActive delivers unmatched innovation.

go back to PRESS RELEASES